Future of monoclonal antibodies in the treatment of hematologic malignancies

Cancer Control

Volumn 9, Issue 2, 2002, Pages 152-166

  Reff, Mitchell E ^a   Hariharan, Kandasamy ^a   Braslawsky, Gary ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 114; MONOCLONAL ANTIBODY IDEC 152; PREDNISONE; PRIMATIZED; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD DISEASE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; HUMAN; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIATION DOSE; RADIOIMMUNOTHERAPY;

EID: 0036240463     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900207     Document Type: Article

References (126)

1. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
2. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy
3. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains
4. A humanized antibody that binds to the interleukin 2 receptor
5. "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4
6. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
7. By-passing immunization human antibodies from v-gene libraries displayed on phage
8. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
9. Humanized monoclonal antibody CAMPATH-1H: Myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material
10. Antibodies generated from human immunoglobulin miniloci in transgenic mice
11. Manipulation of human minichromosomes to carry greater than megabase-sized chromosome inserts
12. High-throughput generation and engineering of recombinant human antibodies
13. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis
14. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
15. Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody
16. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics
17. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys
18. Targeting of tumors with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: Immunolocalisation, pharmacokinetics and immune response
19. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytical virus in premature infants and infants with bronchopulmonary dysplasia
20. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis
21. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients
22. High-frequency loss of specific immunoglobulin production in hybridoma cell lines bearing a chromosomal immunoglobulin kappa gene modified by homologous recombination
23. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states
24. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First communication: Plasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits
25. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA)
26. Human anti-mouse antibodies
27. Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier
28. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
29. Improving antibody affinity by mimicking somatic hypermutation in vitro
30. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized MAb
31. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity
32. By-passing immunization building high affinity human antibodies by chain shuffling
33. Human antibody effector function
34. Production of characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide
35. Mapping of the c1q binding site on Rituxan, a chimeric antibody with a human IgG Fc
36. Studies of aglycosylated chimeric mouse-human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
37. High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR
38. Formation of bispecific antibody by the use of leucine zippers
39. Expression and characterization of a chimeric bifunctional antibody with therapeutic applications
40. CD3X anti-nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors
41. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct
42. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy
43. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein
44. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
45. B cell antigen receptor-mediated apoptosis: Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking
46. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
47. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis
48. Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways
49. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
50. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain
51. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody
52. Finally! The Brambell receptor (FcRB): Mediator of transmission of immunity and protection from catabolism for IgG
53. FcRn: The MHC class I-related receptor that is more than an IgG transporter
54. Immunoglobin-like domains with increased half lives
55. The protection receptor for IgG catabolism is the b2-microglobulin-containing neonatal intestinal transport receptor
56. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
57. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
58. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
59. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma
60. Phase II study of fit rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
61. MAbthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
62. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
63. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
64. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
65. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer
66. Interferon-gamma and monoclonal antibody 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer
67. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon
68. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia
69. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system
70. Pretargeting: General principles; October 10-12, 1996
71. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results
72. Reduced antibody response to streptavidin through site-directed mutagenesis
73. Pretargeting with the affinity enhancement system for radioimmunotherapy
74. Targeted toxins
75. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
76. BR96 sFv-PE40, a potent single-chain immunotoxin that select kills carcinoma cells
77. Immunotoxins for the treatment of leukaemia
78. Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms
79. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion
80. Continuous Infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
81. The effect of a monoclonal antibody coupled to ricin a chain-derived peptides on endothelial cells in vitro: Insights into toxin-mediated vascular damage
82. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: Tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models
83. Chemical modifications of proteins: History and applications
84. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
85. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing
86. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity
87. Tumor penetration and functional activity of BMS-182248 following administration in a phase I clinical trial
88. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
89. The enediyne antibiotics
90. Mechanisms of target selection by DNA-damaging chemicals: Studies with enediyne anticancer drugs
91. Maytansine
92. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumore antibiotics
93. Targeted therapy with a novel enediyne antibiotic calicheamicin theta(I) 1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma
94. Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using antibody-drug conjugate
95. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
96. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
97. Folate-maytansinoids: Target-selective drugs of low molecular weight
98. A summary of monoclonal antibodyenzyme/prodrug
99. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy
100. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate
101. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing
102. Multiple event activation of a generic prodrug trigger by antibody catalysis
103. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies
104. Phase I/II of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
105. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effects of dose and EDTA coadministration on pharmacokinetics and toxicity
106. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
107. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers
108. Pharmacokinetics of human-mouse chimeric anti-GD2 MAb ch14.18 in a phase I trial in neuroblastoma patients
109. CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
110. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses
111. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma4) monoclonal antibody in humans
112. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies
113. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
114. Targeting of liver metastases of colorectal cancer with IgG, F(ab') 2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: The role of metabolism and kinetics
115. Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer
116. Taking engineered anti-CEA antibodies to the clinic
117. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
118. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments
119. Therapeutic antibody fragments with prolonged in vivo half-lives
120. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion
121. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2
122. Secretion of a single-gene-encoded immunoglobulin from myeloma cells
123. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins
124. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
125. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
126. Signaling antibodies in cancer therapy